Steve Grauer
Overview
Explore the profile of Steve Grauer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
410
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bloomingdale P, Bumbaca-Yadav D, Sugam J, Grauer S, Smith B, Antonenko S, et al.
Front Pharmacol
. 2022 Sep;
13:867457.
PMID: 36120380
Disrupted tau proteostasis and transneuronal spread is a pathological hallmark of Alzheimer's disease. Neurodegenerative diseases remain an unmet medical need and novel disease modifying therapeutics are paramount. Our objective was...
2.
Malamas M, Stange H, Schindler R, Lankau H, Grunwald C, Langen B, et al.
Bioorg Med Chem Lett
. 2012 Aug;
22(18):5876-84.
PMID: 22902656
The identification of highly potent and orally active triazines for the inhibition of PDE10A is reported. The new analogs exhibit low-nanomolar potency for PDE10A, demonstrate high selectivity against all other...
3.
Malamas M, Ni Y, Erdei J, Stange H, Schindler R, Lankau H, et al.
J Med Chem
. 2011 Oct;
54(21):7621-38.
PMID: 21988093
The identification of highly potent and orally active phenylpyrazines for the inhibition of PDE10A is reported. The new analogues exhibit subnanomolar potency for PDE10A, demonstrate high selectivity against all other...
4.
Ghiron C, Haydar S, Aschmies S, Bothmann H, Castaldo C, Cocconcelli G, et al.
J Med Chem
. 2010 May;
53(11):4379-89.
PMID: 20465311
Alpha-7 nicotinic acetylcholine receptor (alpha7 nAChR) agonists are promising therapeutic candidates for the treatment of cognitive impairment. We report a series of novel, potent small molecule agonists (4-18) of the...
5.
Liu F, Grauer S, Kelley C, Navarra R, Graf R, Zhang G, et al.
J Pharmacol Exp Ther
. 2008 Aug;
327(3):827-39.
PMID: 18753411
Positive allosteric modulators (PAMs) of metabotropic glutamate receptor subtype 5 (mGlu5) enhance N-methyl-d-aspartate receptor function and may represent a novel approach for the treatment of schizophrenia. ADX47273 [S-(4-fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-methanone], a recently...
6.
Liu F, Day M, Muniz L, Bitran D, Arias R, Revilla-Sanchez R, et al.
Nat Neurosci
. 2008 Feb;
11(3):334-43.
PMID: 18297067
Estrogens have long been implicated in influencing cognitive processes, yet the molecular mechanisms underlying these effects and the roles of the estrogen receptors alpha (ERalpha) and beta (ERbeta) remain unclear....
7.
Rosenzweig-Lipson S, Sabb A, Stack G, Mitchell P, Lucki I, Malberg J, et al.
Psychopharmacology (Berl)
. 2007 Feb;
192(2):159-70.
PMID: 17297636
Rationale: Activation of one or more of the serotonin (5-HT) receptors may play a role in mediating the antidepressant effects of SSRIs. Objective: The present studies were conducted to evaluate...